Keywords: xtl, biopharma, licenses, preclinical, antiviral, program, presidio

XTL Biopharma licenses preclinical antiviral program to Presidio for up to $108M

Article | 31 March 2008

Print This

USA-based XTL Biopharmaceuticals has licensed its preclinical program focused on the NS5A target of the hepatitis C virus to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in